Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $190.00 Price Target at JPMorgan Chase & Co. : vimarsana.com

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its target price boosted by stock analysts at JPMorgan Chase & Co. from $170.00 to $190.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential […]

Related Keywords

United States , Patricia Carr , Philipl Johnson , Stifel Nicolaus , Piper Sandler , News Ratings For Jazz Pharmaceuticals Daily , Jazz Pharmaceuticals Price Performance , Securities Exchange Commission , Covestor Ltd , Analyst Recommendations For Jazz Pharmaceuticals , Jpmorgan Chase Co , Jazz Pharmaceuticals , Barclays , Cantor Fitzgerald , Assetmark Inc , Insider Transactions At Jazz Pharmaceuticals , St Germaindj Co , Cape Investment Advisory Inc , Get Free Report , Exchange Commission , Investment Advisory , Spire Wealth Management , Wealth Management , Jazz Pharmaceuticals Daily , Nasdaq Jazz , Jazz , Medical , G5087110 , Boost Price Target , Jpmorgan Chase Amp Co ,